Åslaug Helland

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial

David Planchard, Egbert F. Smit, Harry J.M. Groen et al. · The Lancet Oncology · 2017 · 1.4K citations · Full text

Medicine, Oncology, Pharmacology +11

Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers

Jen‐Tsan Chi, Zhen Wang, Dimitry S.A. Nuyten et al. · PLoS Medicine · 2006 · 615 citations · Full text

Life Sciences, Oncology, Physiology +15

Mutations in the <i>DDR2</i> Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

Peter S. Hammerman, Martin L. Sos, Alex H. Ramos et al. · Cancer Discovery · 2011 · 472 citations · Full text

Medicine, Genetics, Oncology +16

Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking

Joachim Weischenfeldt, Taronish D. Dubash, Alexandros P. Drainas et al. · Nature Genetics · 2016 · 430 citations · Full text

Medicine, Genetics, Molecular Genetics +16

Integrative genomic profiling of large-cell neuroendocrine carcinomas reveals distinct subtypes of high-grade neuroendocrine lung tumors

Julie George, Vonn Walter, Martin Peifer et al. · Nature Communications · 2018 · 373 citations · Full text

Medicine, Molecular Genetics, Oncology +17